Kenvue Brands

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Activity

Key Events

Aug 20, 2026TrialA Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin

Aug 6, 2026TrialA Pilot Study to Evaluate the Expanded Reach of Decentralized Digital Skin Health Clinical Studies

Jul 11, 2026TrialA Single Center, Controlled Study to Evaluate the Ability of Sunscreen Products to Modulate the Effects of Deep UVA +/- HEV Blue Light Induced Pigmentation and Biomarkers of Cutaneous Oxidative Stress

Jul 2, 2026TrialA Monocentric and Open-Label Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Research Participants

Feb 12, 2026FDAPepcid — PEPCID AC

Oct 22, 2025FDATylenol — ACETAMINOPHEN AND IBUPROFEN

4 more events

Sep 30, 2025FDAPepcid — PEPCID COMPLETE

Jul 16, 2025FDAPepcid — FAMOTIDINE

Feb 11, 2025FDAPepcid — PEPCID COMPLETE

Jan 31, 2025FDAPepcid — PEPCID COMPLETE

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

15 patent groups across drugs · Source: FDA Orange Book

DrugExpires

RhofadeMay 2, 2028 Tylenol3 patentsNov 13, 2028 Tylenol3 patentsMay 13, 2029 Advil6 patentsSep 30, 2029 Zyrtec9 patentsFeb 11, 2030 TylenolApr 19, 2030 AdvilSep 14, 2030 Rhofade4 patentsAug 26, 2031

7 more

TylenolSep 11, 2031 TylenolMar 11, 2032 Advil3 patentsMar 16, 2032 ZyrtecJul 9, 2032 ZyrtecJan 9, 2033 Rhofade5 patentsJun 11, 2035 Rhofade11 patentsDec 15, 2039

Regulatory

Regulatory Timeline

20212 events

FDAFeb 18

Tylenol — ACETAMINOPHEN

Application NDA204957 (NDA)

FDAFeb 18

Injectapap — ACETAMINOPHEN

Application NDA204957 (NDA)

20226 events

FDADec 15

Pepcid — PEPCID AC

Application NDA020325

FDAJun 3

Tylenol — ACETAMINOPHEN

Application NDA206968 (NDA)

FDAJun 3

Injectapap — ACETAMINOPHEN

Application NDA206968 (NDA)

FDAJun 3

Injectapap — ACETAMINOPHEN

Application NDA206968 (NDA)

FDAJun 3

Injectapap — ACETAMINOPHEN

Application NDA206968 (NDA)

FDAFeb 18

Pepcid — PEPCID AC

Application NDA020325

20232 events

FDADec 14

Pepcid — PEPCID AC

Application NDA020325

FDAFeb 28

Tylenol — ACETAMINOPHEN AND IBUPROFEN

Application ANDA214836

20241 event

FDAJan 18

Tylenol — ACETAMINOPHEN

Application ANDA211544

20258 events

FDAOct 22

Tylenol — ACETAMINOPHEN AND IBUPROFEN

Application ANDA214836

FDAOct 22

Tylenol — ACETAMINOPHEN AND IBUPROFEN

Application ANDA214836

FDAOct 22

Tylenol — ACETAMINOPHEN AND IBUPROFEN

Application ANDA214836

FDASep 30

Pepcid — PEPCID COMPLETE

Application NDA020958

FDAJul 16

Pepcid — FAMOTIDINE

Application NDA219935 (NDA)

FDAFeb 11

Pepcid — PEPCID COMPLETE

Application NDA020958

FDAJan 31

Pepcid — PEPCID COMPLETE

Application NDA020958

FDAJan 17

Pepcid — PEPCID COMPLETE

Application NDA020958

20261 event

FDAFeb 12

Pepcid — PEPCID AC

Application NDA020325

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)